Affiliation:
1. Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds, United Kingdom
Abstract
Abstract
The importance of the prostaglandin (PG) synthesis pathway, particularly the rate-limiting enzymatic step catalyzed by cyclooxygenase, to colorectal carcinogenesis and development of novel anticolorectal cancer therapy is well established. The predominant PG species in benign and malignant colorectal tumors is PGE2. PGE2 acts via four EP receptors termed EP1 to EP4. Recently, EP receptors have been identified as potential targets for treatment and/or prevention of colorectal cancer. This review summarizes existing knowledge of the expression and function of the EP receptor subtypes in human and rodent intestine during tumorigenic progression and describes the current literature on targeting EP receptor signaling during intestinal tumorigenesis.
Publisher
American Association for Cancer Research (AACR)
Reference90 articles.
1. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11–21.
2. Ota S, Bamba H, Kato A, Kawamoto C, Yoshida Y, Fujiwara K. COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther 2002;16 Suppl 2:102–6.
3. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871–5.
4. Gupta RA, DuBois RN. Controversy: PPARγ as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002;283:G266–9.
5. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705–8.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献